List of Excipients in Branded Drug RIVASTIGMINE TARTRATE

« Back to Dashboard

Generic Drugs Containing RIVASTIGMINE TARTRATE

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	rivastigmine tartrate	0904-6587	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	rivastigmine tartrate	0904-6587	FERRIC OXIDE RED
Major Pharmaceuticals	rivastigmine tartrate	0904-6587	FERRIC OXIDE YELLOW
Major Pharmaceuticals	rivastigmine tartrate	0904-6587	GELATIN
Major Pharmaceuticals	rivastigmine tartrate	0904-6587	HYPROMELLOSE

What are the Most Frequently-Used Excipients in RIVASTIGMINE TARTRATE?

# Of NDCs	Excipient
3	ALCOHOL
6	AMMONIA
3	BUTYL ALCOHOL
21	CELLULOSE, MICROCRYSTALLINE
3	D&C RED NO. 28

Rivastigmine Tartrate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Rivastigmine tartrate is an established acetylcholinesterase inhibitor used for mild-to-moderate Alzheimer’s dementia and Parkinson’s disease dementia. The molecule is commercially mature, with generic oral capsules and oral solution products competing against Exelon. The strongest excipient opportunities are in taste masking, dose uniformity, moisture control, modified release, and patient-friendly multiparticulate systems rather than in basic immediate-release capsules.

The commercial opportunity is concentrated in three areas:

1. Lower-cost and differentiated oral solid-dose products.
2. Oral solutions and pediatric-style administration technologies adapted for elderly patients with dysphagia.
3. Transdermal and long-acting delivery systems that reduce gastrointestinal exposure and dosing frequency.

What is rivastigmine tartrate and how is it formulated?

Rivastigmine tartrate is the tartrate salt of rivastigmine. Oral products are labeled according to the amount of rivastigmine base delivered, although the active pharmaceutical ingredient is rivastigmine tartrate.

Exelon capsules were approved in the United States in 2000. Exelon oral solution followed as an oral liquid product. The transdermal patch was approved in 2007 and uses rivastigmine in a delivery system distinct from the oral tartrate products.[1][2]

Common oral dosage forms

Dosage form	Typical strengths or delivery	Primary formulation issue
Immediate-release capsule	1.5 mg, 3 mg, 4.5 mg, 6 mg rivastigmine base equivalent	Dose uniformity, capsule fill, moisture control
Oral solution	2 mg/mL rivastigmine base equivalent	Chemical stability, taste, preservative system
Transdermal patch	4.6, 9.5 and 13.3 mg delivered per 24 hours	Adhesion, controlled permeation, skin tolerability
Emerging multiparticulate systems	Dose-dependent	Taste masking, sprinkle administration, controlled release

The oral capsule is generally a conventional hard-gelatin dosage form. The formulation platform is technically accessible, which explains the availability of generic products. The commercial differentiation challenge is therefore not basic formulation replication. It is improving administration, tolerability, stability, or supply economics.

What excipients are used in rivastigmine tartrate capsules?

The Exelon capsule label identifies conventional excipients including gelatin, magnesium stearate, microcrystalline cellulose, silicon dioxide, titanium dioxide, and colorants such as iron oxides, depending on capsule strength.[1]

Generic products may use different excipient systems if they meet pharmaceutical equivalence, bioequivalence, quality, and labeling requirements. Typical functional categories include:

Excipient function	Candidate materials	Commercial purpose
Dilution and compressibility	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls fill weight and content uniformity
Flow improvement	Colloidal silicon dioxide	Improves powder handling and capsule filling
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and equipment friction
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid capsule plug dispersion
Moisture control	Low-moisture excipients, desiccant packaging, protective coatings	Limits degradation and fill variability
Color and identification	Iron oxides, titanium dioxide where permitted	Supports product differentiation and strength identification
Capsule shell	Gelatin or hypromellose	Enables vegetarian or religiously compliant alternatives

Rivastigmine tartrate has a relatively low dose, making content uniformity more important than bulk drug loading. A formulation with poor powder segregation control can produce unacceptable potency variability even when the blend is chemically stable. Particle-size engineering, ordered mixing, and low-shear handling can have more commercial value than adding a new excipient.

How should manufacturers design an excipient strategy for rivastigmine tartrate?

A commercially effective strategy should begin with dose uniformity and patient acceptability.

Dose uniformity and powder engineering

The highest-priority excipient objective is uniform distribution of rivastigmine tartrate throughout the blend. Manufacturers should evaluate:

• Active particle-size distribution.
• Salt crystallinity and polymorphic behavior.
• Blend segregation during transfer and encapsulation.
• Electrostatic charging.
• Lubricant mixing time.
• Capsule fill-weight variability.
• Assay and content-uniformity performance at the lowest strength.

A high-functionality microcrystalline cellulose grade can provide a robust dilution platform. Colloidal silicon dioxide may improve flow but can also alter blend behavior if overused. Magnesium stearate requires controlled addition because excessive lubrication can affect wetting and dissolution.

Moisture management

Moisture control is relevant to both the active salt and gelatin capsule shell. The preferred approach is usually a low-water-activity formulation supported by high-barrier packaging. Aluminum-aluminum blister packs, cold-form foil, and desiccant-containing high-density polyethylene bottles can reduce exposure during distribution.

The excipient supplier opportunity is strongest where a formulation can demonstrate longer in-use stability, reduced capsule brittleness, or lower dependence on desiccant packaging.

Taste masking and swallowability

Patients with Alzheimer’s and Parkinson’s disease dementia often have swallowing difficulties. Conventional capsules are therefore vulnerable to nonadherence even when the product is pharmacologically effective.

Potential approaches include:

• Sprinkle capsules containing coated pellets.
• Orally disintegrating mini-tablets.
• Taste-masked granules.
• Soft chewable or dispersible dosage forms.
• Low-volume oral suspensions.
• Sachets for administration with soft food.

Taste masking must account for the bitterness of rivastigmine and the acidic character of the tartrate salt. Polymer coatings, ion-exchange resins, lipid barriers, and multiparticulate encapsulation are possible platforms. The commercial advantage depends on maintaining rapid release after administration and avoiding a meaningful change in systemic exposure.

What excipients are used in rivastigmine oral solution?

The Exelon oral solution contains rivastigmine tartrate in an aqueous vehicle. Label information identifies citric acid, sodium benzoate, and purified water among the inactive ingredients.[2]

The oral solution presents a different excipient opportunity from capsules. Key formulation targets include:

• pH control.
• Chemical stability.
• Preservative effectiveness.
• Metal-ion control.
• Palatability.
• Accurate dosing from the supplied oral syringe or measuring device.
• Compatibility with bottles, closures, and dosing accessories.

Citric acid can support pH adjustment and palatability. Sodium benzoate provides antimicrobial preservation, subject to concentration, pH, and regulatory limits. Preservative choice must be assessed against elderly-patient tolerability and regional excipient restrictions.

A differentiated generic oral solution could compete through lower dosing error, improved taste, preservative-free packaging, unit-dose delivery, or a ready-to-use presentation. These opportunities require strong stability data because liquid formulations create greater chemical and microbiological burdens than capsules.

What formulation patents protect rivastigmine products?

The original Exelon product patents and regulatory exclusivities have expired for the principal oral products. Generic rivastigmine capsules and oral solutions have been approved in the United States, and the basic immediate-release dosage form is not a high-barrier product category.[3]

The principal historical patent estate was associated with Novartis and predecessor rights relating to rivastigmine, its pharmaceutical salts, formulations, and therapeutic uses. The commercial importance of those rights has declined as core composition and oral-product exclusivities expired.

Current protection may still arise from:

• Newly filed controlled-release formulations.
• Transdermal delivery systems.
• Adhesive compositions.
• Skin-permeation technologies.
• Specific dosing regimens.
• Combination products.
• Manufacturing processes.
• Device or packaging configurations.

A product-by-product review of the current USPTO, FDA Orange Book, and international registers is required before relying on any specific patent expiration date. Patent status can differ by jurisdiction and by dosage form.

What is the FDA and Orange Book status of rivastigmine tartrate?

Rivastigmine oral capsules and oral solution are FDA-approved generic drug products. The FDA Orange Book identifies approved reference-listed drugs and therapeutic-equivalence information for approved generic products.[3]

The competitive regulatory position is materially different by product:

Product	Regulatory position	Entry barrier
Immediate-release capsules	Multiple approved generics	Low
Oral solution	Generic competition, but fewer formulation options	Moderate
Transdermal patch	More complex delivery system	Higher
New extended-release product	Likely requires differentiated clinical and CMC package	High
Biosimilar pathway	Not applicable	No biosimilar route

Rivastigmine is a small molecule, so biosimilar risk does not apply. Competition comes from abbreviated new drug applications, 505(b)(2) applications, and, for materially novel delivery systems, potentially a full or hybrid development strategy.

When did rivastigmine lose exclusivity, and what generic entry risks remain?

The principal oral exclusivity period has ended, and generic entry is established. The remaining risks are commercial rather than basic molecule-level patent risks.

Paragraph IV challenges

Paragraph IV certifications are most relevant where an ANDA applicant seeks approval before the expiration of an Orange Book-listed patent. For legacy immediate-release rivastigmine products, the practical barrier from the original patent estate is limited because generic products are already marketed.

Future Paragraph IV activity could target:

• New oral liquid formulations.
• Sprinkle or multiparticulate products.
• Controlled-release dosage forms.
• Transdermal systems.
• Method-of-use patents with commercially relevant labeling restrictions.

Generic launch scenarios

Launch scenario	Commercial effect
Additional capsule supplier	Price erosion and pharmacy substitution
Low-cost oral solution	Pressure on branded and existing generic liquid products
Sprinkle formulation	Premium pricing based on adherence and swallowing benefits
Extended-release product	Potentially slower titration and reduced dosing burden
Improved patch or adhesive system	Competition with branded transdermal products
Regional contract-manufactured product	Lower procurement cost in tender markets

The largest risk to a new capsule entrant is rapid price compression. The strongest opportunity is a product with a clinically meaningful administration advantage that supports noncommodity pricing.

How strong is the rivastigmine patent estate?

The legacy patent estate is weak for standard oral capsules because the basic active ingredient and established immediate-release formats are commercially genericized. The estate can be stronger for differentiated delivery systems.

Asset type	Relative strength	Reason
Basic rivastigmine tartrate capsule	Low	Mature product and generic competition
Conventional oral solution	Low to moderate	Formulation replication is feasible
Taste-masked multiparticulates	Moderate	Performance and formulation claims may create differentiation
Extended-release oral product	Moderate to high	Release profile and clinical performance can be harder to design around
Transdermal adhesive or permeation system	Moderate to high	Device, adhesive, and formulation claims may overlap
Manufacturing process	Variable	Strength depends on process specificity and reproducibility
Method of use	Variable	Scope depends on claim language and approved labeling

Patent strength should be assessed claim by claim. A broad formulation patent with an easily substituted excipient system has limited blocking value. A patent tied to a specific release profile, adhesion performance, or clinically demonstrated dosing regimen is more defensible.

What commercial opportunities exist for excipient suppliers?

The largest opportunities are in functional excipients that solve measurable product problems.

High-value excipient opportunities

1. Taste-masking polymers for granules, pellets, and orally disintegrating products.
2. Low-moisture diluent systems for low-dose capsules.
3. Co-processed excipients that improve content uniformity and capsule-filling speed.
4. Preservative and buffer systems for oral solutions.
5. Bioadhesive or permeation-controlling materials for transdermal products.
6. Hypromellose or other capsule shells for vegetarian and regional-market requirements.
7. High-barrier packaging components used with moisture-sensitive fills.
8. Excipient systems that reduce lubricant sensitivity and improve dissolution robustness.

Suppliers with regulatory support packages have an advantage. Generic manufacturers need impurity, elemental impurity, residual solvent, nitrosamine, extractables, leachables, and global compendial documentation. A technically adequate excipient without a complete regulatory file can delay development.

How does rivastigmine compare with competing dementia drugs?

Drug	Main dosage forms	Excipient and delivery opportunity
Rivastigmine	Capsules, oral solution, patch	Strongest opportunity in adherence and transdermal systems
Donepezil	Tablets, orally disintegrating tablets, solution in some markets	Mature ODT and taste-masking competition
Galantamine	Capsules, tablets, oral solution	Modified-release and liquid dosing
Memantine	Tablets, capsules, oral solution	Combination products and oral liquid systems

Rivastigmine has a distinctive commercial position because its transdermal delivery route is established and clinically recognized. That creates a broader formulation opportunity than for many oral-only acetylcholinesterase inhibitors. It also creates a higher technical barrier for patch development.

What licensing and partnership opportunities exist?

Licensing opportunities are most credible in differentiated delivery technologies rather than in standard rivastigmine tartrate capsules.

Potential transaction structures include:

• Regional licensing of a generic oral solution.
• Co-development of a sprinkle or multiparticulate product.
• Excipient supplier agreements tied to a proprietary taste-masking platform.
• Contract development and manufacturing for transdermal systems.
• Licensing of a controlled-release formulation outside major markets.
• Supply agreements for high-barrier packaging or specialty capsule shells.

A standard capsule formulation is unlikely to command significant licensing value unless it has a cost advantage, supply-security benefit, or market-specific regulatory clearance.

What geographic markets offer the best opportunities?

The United States has established generic competition and significant price pressure. Europe has a fragmented market in which supply reliability, national reimbursement, and tender access influence commercial performance. Emerging markets may offer better opportunities for oral solutions, lower-cost capsules, and locally manufactured products, but registration requirements and procurement structures vary.

Transdermal systems may support higher value in markets where adherence, caregiver administration, and reduced gastrointestinal exposure have strong clinical or reimbursement relevance. Oral liquids and sprinkle formulations may be particularly relevant where dementia care relies heavily on caregivers and swallowing limitations are common.

Key Takeaways

• Rivastigmine tartrate capsules are mature, low-barrier generic products.
• The most attractive excipient strategies focus on dose uniformity, moisture control, taste masking, and swallowability.
• Oral solution opportunities depend on stability, preservative performance, dosing accuracy, and palatability.
• Transdermal delivery remains the strongest higher-value formulation platform.
• Biosimilar competition is irrelevant because rivastigmine is a small molecule.
• The legacy oral patent estate provides limited protection against generic entry.
• New formulation, method-of-use, manufacturing, and transdermal patents can still create commercial barriers.
• Excipient suppliers should prioritize multifunctional materials supported by complete regulatory documentation.
• Licensing value is more likely in differentiated delivery technology than in a conventional capsule blend.

FAQs

Is rivastigmine tartrate the same as rivastigmine base?

No. Rivastigmine tartrate is the pharmaceutical salt, while product labeling generally expresses dose strength as rivastigmine base equivalent.

Can rivastigmine tartrate be formulated as a sprinkle capsule?

Yes. Multiparticulate or coated-pellet systems are technically feasible, but taste masking, dose uniformity, release performance, and food compatibility must be demonstrated.

Which excipient is most important for rivastigmine capsule uniformity?

No single excipient determines performance. The combination of a suitable diluent, flow aid, controlled lubricant level, and engineered active-particle distribution is more important.

Does rivastigmine have biosimilar competition?

No. Rivastigmine is a small-molecule drug and competes through generic-drug pathways rather than biosimilar regulation.

Is a rivastigmine oral solution commercially differentiated?

It can be, but differentiation requires more than matching the reference product. Improved taste, dosing accuracy, stability, preservative strategy, packaging, or caregiver usability is needed to support a premium position.

References

1. Novartis Pharmaceuticals Corporation. (2023). Exelon (rivastigmine tartrate) capsules prescribing information. U.S. Food and Drug Administration.

2. Novartis Pharmaceuticals Corporation. (2023). Exelon (rivastigmine tartrate) oral solution prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/